Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of IL-YANG Influenza Vaccine vs Fluarix in Healthy Korean Men
NCT02330003Phase 1Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- May 2013
- Primary completion
- Aug 2013
01
Overview
Phase 1, randomised, open-label trial in influenza (2 arms), sponsored by Il-Yang Pharmaceutical. Primary endpoints: Solicited local & general Adverse Event, Unsolicited Adverse Event at Day 28, Percentage of subjects achieving seroconversion for HI antibody at Day 28 and 1 more. Started May 2013; status: completed.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT02330003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02330003.